Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colistin vs Colistin + Cefoperazone-sulbactam for MDR-AB VAP
NCT07671755Completed
- Sponsor
- Shaheed Mohtarma Benazir Bhutto Institute of Trauma
- Start
- Feb 2025
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Trial of cefoperazone + sulbactam in ventilator-associated pneumonia (VAP) (2 arms), sponsored by Shaheed Mohtarma Benazir Bhutto Institute of Trauma. Primary endpoint: Clinical response at 1 week. Started Feb 2025; status: completed.
02
Drugs
cefoperazone + sulbactam
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT07671755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07671755.